These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34293430)

  • 1. Application of in vitro data in physiologically-based kinetic models for quantitative in vitro-in vivo extrapolation: A case-study for baclofen.
    Kasteel EEJ; Lautz LS; Culot M; Kramer NI; Zwartsen A
    Toxicol In Vitro; 2021 Oct; 76():105223. PubMed ID: 34293430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intrathecal baclofen. Experimental and pharmacokinetic studies].
    Sallerin B; Lazorthes Y
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):271-5. PubMed ID: 12746702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations.
    Vlavonou R; Perreault MM; Barrière O; Shink E; Tremblay PO; Larouche R; Pichette V; Tanguay M
    J Clin Pharmacol; 2014 May; 54(5):584-92. PubMed ID: 24414993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients.
    Chevillard L; Sabo N; Tod M; Labat L; Chasport C; Chevaleyre C; Thibaut F; Barré J; Azuar J; Questel F; Vorspan F; Bloch V; Bellivier F; Granger B; Barrault C; Declèves X
    Fundam Clin Pharmacol; 2018 Apr; 32(2):239-248. PubMed ID: 29091319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating in vitro chemical transplacental passage into a generic PBK model: A QIVIVE approach.
    Fragki S; Hoogenveen R; van Oostrom C; Schwillens P; Piersma AH; Zeilmaker MJ
    Toxicology; 2022 Jan; 465():153060. PubMed ID: 34871708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro to in vivo extrapolation of effective dosimetry in developmental toxicity testing: Application of a generic PBK modelling approach.
    Fragki S; Piersma AH; Rorije E; Zeilmaker MJ
    Toxicol Appl Pharmacol; 2017 Oct; 332():109-120. PubMed ID: 28760446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid baclofen concentrations in patients undergoing continuous intrathecal baclofen therapy.
    Albright AL; Thompson K; Carlos S; Minnigh MB
    Dev Med Child Neurol; 2007 Jun; 49(6):423-5. PubMed ID: 17518926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.
    Najjar A; Punt A; Wambaugh J; Paini A; Ellison C; Fragki S; Bianchi E; Zhang F; Westerhout J; Mueller D; Li H; Shi Q; Gant TW; Botham P; Bars R; Piersma A; van Ravenzwaay B; Kramer NI
    Arch Toxicol; 2022 Dec; 96(12):3407-3419. PubMed ID: 36063173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs.
    Flack SH; Bernards CM
    Anesthesiology; 2010 Jan; 112(1):165-73. PubMed ID: 19996952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intrathecal baclofen therapy in brain injury and recovery of persistent vegetative state. Apropos of a case].
    Espigares Correa G; Benito-Penalva J
    Rehabilitacion (Madr); 2020; 54(2):137-141. PubMed ID: 32370828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity.
    Heetla HW; Proost JH; Molmans BH; Staal MJ; van Laar T
    Br J Clin Pharmacol; 2016 Jan; 81(1):101-12. PubMed ID: 27099877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time course of the effect of a bolus dose of intrathecal baclofen on severe cerebral spasticity.
    Pohl M; Rockstroh G; Rückriem S; Mehrholz J; Pause M; Koch R; Strik H
    J Neurol; 2003 Oct; 250(10):1195-200. PubMed ID: 14586601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Baclofen for alcohol addiction].
    Helland A; Bramness JG
    Tidsskr Nor Laegeforen; 2011 Nov; 131(21):2132-3. PubMed ID: 22048211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of stretch reflex activity after spinal or systemic treatment with AMPA receptor antagonist NGX424 in rats with developed baclofen tolerance.
    Oshiro M; Hefferan MP; Kakinohana O; Lukacova N; Sugahara K; Yaksh TL; Marsala M
    Br J Pharmacol; 2010 Nov; 161(5):976-85. PubMed ID: 20977450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone.
    Shi M; Bouwmeester H; Rietjens IMCM; Strikwold M
    Arch Toxicol; 2020 Aug; 94(8):2809-2827. PubMed ID: 32367273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baclofen-loaded solid lipid nanoparticles: preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration.
    Priano L; Zara GP; El-Assawy N; Cattaldo S; Muntoni E; Milano E; Serpe L; Musicanti C; Pérot C; Gasco MR; Miscio G; Mauro A
    Eur J Pharm Biopharm; 2011 Sep; 79(1):135-41. PubMed ID: 21352914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baclofen withdrawal following removal of an intrathecal baclofen pump despite oral baclofen replacement.
    Greenberg MI; Hendrickson RG
    J Toxicol Clin Toxicol; 2003; 41(1):83-5. PubMed ID: 12645974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential correlation of intrathecal baclofen concentration and clinical improvement after high dose intrathecal intoxication: a case report.
    Mahvash M; Maslehaty H; Warneke N; Doukas A; Petridis AK; Mehdorn HM
    Clin Neurol Neurosurg; 2011 Nov; 113(9):806-7. PubMed ID: 21889255
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical tolerance and toxicity of intravenous baclofen: a pilot study in a canine model.
    Krach LE; Kriel RL; Patterson EE; Scherkenbach LA; Coles LD; Cloyd JC
    J Pediatr Rehabil Med; 2011; 4(2):89-98. PubMed ID: 21955965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin.
    Armstrong RW; Steinbok P; Cochrane DD; Kube SD; Fife SE; Farrell K
    J Neurosurg; 1997 Sep; 87(3):409-14. PubMed ID: 9285607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.